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1. Introduction 
Lamellarins are polyaromatic marine alkaloids that possess a 
unique 14-phenyl-6H-[1]benzopyrano[4’,3’:4,5]pyrrolo[2,1-
a]isoquinolin-6-one framework.1 Up to now, approximately 40 
lamellarins have been isolated from mollusks, tunicates, and 
sponges.2 These differ in the number and position of the OH and 
OMe groups on the common structural core. Lamellarins exhibit 
a wide range of useful biological activities; most notable is potent 
cytotoxic activity against cancer cell lines, including the MDR 
phenotype.3 Extensive studies on structure–activity relationship 
have revealed the structural requirements for the cytotoxicity.4 
Multiple cellular targets, such as DNA topoisomerase I,5 cancer-
relevant protein kinases,6 and mitochondria,7 have been 
discovered. Some lamellarin derivatives are currently under 
preclinical development as anti-cancer agents.8  
Anti-HIV-1 activity is another important biological effect of 
lamellarins. Faulkner and coworkers screened diverse natural 
marine products for compounds active against HIV-1 integrase in 
vitro and found that some lamellarins showed selective inhibition 
for this enzyme.9 Within the series of lamellarins tested, 
lamellarin α 20-sulfate displayed the most favorable therapeutic 
index. This compound inhibited integrase terminal cleavage 
activity with an IC50 of 16 µM, strand transfer activity with an 
IC50 of 22 µM, and growth of the HIV-1 virus in cell culture with 
an IC50 of 8 µM. The MTT assay of lamellarin α 20-sulfate 
toward HeLa cells displayed the least toxicity of 274 µM.  
Despite the promising feature of lamellarin α 20-sulfate as a 
new lead anti-HIV-1 agent, the structure–activity relationships of 
lamellarin sulfates have scarcely been investigated.10 This is 
presumably due to the lack of a methodology for the synthesis of 
regioselectively sulfated lamellarins. Recently, however, we have 
developed a method to overcome this problem and achieved the 
first total synthesis of lamellarin α 20-sulfate11 and related 
compounds.12 In the present study, we have synthesized non-
sulfated lamellarin α (1) and six different types of sulfated 
lamellarins 2–7 and investigated the structure–activity 
relationships using single-round HIV-1 vector infection assay. A 
plausible mechanism of action of the lamellarin sulfates in vivo is 
also proposed.  
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Lamellarin  α and six different types of lamellarin α 20-sulfate analogues were synthesized and 
their structure–activity relationships were investigated using a single round HIV-1 vector 
infection assay. All lamellarin sulfates having pentacyclic lamellarin core exhibited anti-HIV-1 
activity at a 10  µM concentration range regardless of the number and position of the sulfate 
group. On the other hand, non-sulfated lamellarin  α and ring-opened lamellarin sulfate 
analogues did not affect HIV-1 vector infection in similar concentrations. The lamellarin sulfates 
utilized in this study did not exhibit unfavorable cytotoxic effect under the concentrations tested 
(IC50 > 100 µM). Confocal laser scanning microscopic analysis indicated that hydrophilic 
lamellarin sulfates were hardly incorporated in the cell. HIV-1 Env-mediated cell–cell fusion 
was suppressed by lamellarin sulfates. These results suggested that lamellarin sulfates have a 
novel anti-HIV-1 activity besides the previously reported integrase activity inhibition, possibly 
at a viral entry step of HIV-1 replication.  
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2. Results and discussion 
2.1. Synthesis 
The synthesis of lamellarin α (1), ring-opened lamellarin 
sulfate (2), lamellarin U 20-sulfate (3), lamellarin α 20-sulfate 
(4), and lamellarin α 13-sulfate (5) is show in Scheme 1. 
Palladium-catalyzed Suzuki–Miyaura coupling of the known 3,4-
dihydroxypyrrole bistriflate 813 with 1.2 equiv of arylboronic acid 
9 gave the mono-arylated pyrrole 10 in 77% yield. This 
compound was converted to 11 in 96% yield by deprotection of 
the methoxymethyl (MOM) group followed by acid-catalyzed 
lactonization. The second Suzuki–Miyaura coupling of 11 with 
1.3 equiv of pinacol borate 12 gave 3,4-differentially arylated 
pyrrole 13 in 94% yield. Alkaline hydrolysis of 13 followed by 
pyridinium p-toluenesulfonate (PPTS)-catalyzed relactonization 
afforded the acid 14 in 73 % yield. Decarboxylation of 14 in hot 
quinoline in the presence of copper (I) oxide provided 15 in 
nearly quantitative yield. Intramolecular oxidative biaryl 
coupling14 of 15 in the presence of phenyliodine 
bis(trifluoroacetate) (PIFA)-borontrifluoride etherate gave the 
lamellarin framework 16 in 54% yield. Treatment of this 
compound with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
(DDQ) in refluxing dichloromethane afforded 5,6-unsaturated 
lamellarin 17 in 87% yield. Simultaneous deprotection of both 
benzyl and MOM groups with 6 equiv of boron trichloride 
produced lamellarin α (1) in 98% yield.  
Regioselective installation of the sulfate group onto the 
heterocyclic scaffold of 15, 16, and 17 was effected by selective 
removal of the benzyl or MOM protecting group under different 
conditions followed by sulfation utilizing the Taylor protocol.15 
For example, the sulfate 2 was synthesized from 15 in four steps 
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28 (R1 = Bn, R2 = SO3CH2CCl3)
29 (R1 = H, R2 = SO3CH2CCl3)
(m)
  5 (R1 = H, R2 = SO3Na)(l)
27 (R1 = Bn, R2 = H)(j)25 (R1 = SO3CH2CCl3, R2 = MOM)
26 (R1 = SO3CH2CCl3, R2 = H)
(k)
  4 (R1 = SO3Na, R2 = H)(l)
24 (R1 = H, R2 = MOM)(j)22 (R1 = SO3CH2CCl3, R2 = MOM)
23 (R1 = SO3CH2CCl3, R2 = H)
(k)
  3 (R1 = SO3Na, R2 = H)(l)
21 (R1 = H, R2 = MOM)(j)19 (R1 = SO3CH2CCl3, R2 = MOM)
20 (R1 = SO3CH2CCl3, R2 = H)
(k)
  2 (R1 = SO3Na, R2 = H)(l)
18 (R1 = H, R2 = MOM)(j)
(k)
 
Scheme 1. Synthesis of lamellarin α (1) and sulfated lamellarins 2–5. Reagents and conditions: (a) 9, Pd(PPh3)4, Na2CO3, water, THF, reflux, 3 h (77%); (b) (1) 
concd HCl, MeOH, reflux, 3 h, (2) p-TsOH, CH2Cl2, reflux, 3.5 h (96%); (c) 12, Pd(PPh3)4, Na2CO3, water, THF, reflux, 3 h (94%); (d) (1) 40% aqueous KOH, 
EtOH, reflux, 2 h, (2) PPTS, CH2Cl2, reflux, 8 h (73%); (e) Cu2O, quinoline, 220 °C, 10 min (99%); (f) PIFA, BF3·OEt2, CH2Cl2, –40 °C, 1.5 h (54%); (g) DDQ, 
CH2Cl2, reflux, 30 h (87%); (h) BCl3, CH2Cl2, –78 °C, 0.5 h then 0 °C, 3 h (98%); (i) H2, 10% Pd-C, EtOAc (18: 99%, 21: 98%, 24: 91%); (j) CCl3CH2OSO2Cl, 
Et3N, DMAP, CH2Cl2, (19: 90%, 22: 99%, 25: 99%, 28: 98%); (k) concd HCl, MeOH–CH2Cl2 (1:2) (20: 94%, 23: 92%, 26: 98%, 27: 97%); (l) (1) Zn powder, 
HCO2NH4, THF–MeOH (1:1), (2) Amberlite IRC-50 (Na+ form), (3) Sephadex LH-20 (2: 90%, 3: 71%, 4: 99%, 5: 55%); (m) BCl3, CH2Cl2, –78 °C, 0.5 h then 
0 °C, 1 h (98%). 
the presence of 10% palladium on charcoal gave phenol 18 in 
nearly quantitative yield. This compound was reacted with 2,2,2-
trichloroethyl (TCE) chlorosulfate to give the mixed sulfate 19 in 
90% yield. Deprotection of MOM under acidic conditions 
provided another phenol 20 in 94% yield.  Final reductive 
deprotection of 2,2,2-TCE group with zinc powder in the 
presence of ammonium formate followed by ion exchange over 
IRC-50 (Na+ form) and Sephadex purification produced 2 in 90% 
yield. Lamellarin U 20-sulfate (3) and lamellarin α 20-sulfate (4) 
were synthesized using similar transformations starting from 16 
and 17, respectively. Lamellarin α 13-sulfate (5), on the other 
hand, was synthesized by initial deprotection of MOM followed 
by 2,2,2-trichloroethoxysulfonylation, debenzylation by boron 
trichloride, and a final reductive removal of TCE moiety.  
Lamellarin α 13,20-disulfate (6) and lamellarin N 8,13,20-
trisulfate (7) were synthesized in good yields from lamellarin α 
(1) and lamellarin N (30), respectively, by treatment with 
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Scheme 2. Synthesis of lamellarin sulfates 6 and 7. 
 
2.2. Anti-HIV-1 evaluation 
The anti-HIV-1 activity of lamellarins 1–7 was estimated at 
first by single-round HIV-1 vector infection assays16 on 
HeLa/CD4 cells (see Experimental section). The IC50 values 
estimated from dose-response curves are summarized in Table 1. 
Both non-sulfated lamellarin α (1) and the ring-opened sulfate 
(2) did not show anti-HIV-1 activity at 100 µM (entries 1 and 2). 
On the other hand, sulfates 3–7 exhibited anti-HIV-1 activities at 
a 10 µM concentration range (entries 3–7). When the target cells 
were treated with these compounds at 100 µM, the infected cells 
were not detected. These results indicated that the presence of 
both the pentacyclic lamellarin core and the sulfate group is an 
essential structural requirement for the anti-HIV-1 activity of 
lamellarins. Other structural elements, such as saturation or 
unsaturation between C6 and C7 bond (entries 3 and 4), position 
of the sulfate group in the lamellarin ring (entries 4 and 5), and 
the number of sulfate groups (entries 4, 5, 6, and 7) are relatively 
less important.  
Table 1 
Anti-HIV-1 activity and cytotoxicity of lamellarins 1–7.  
Entry Compound IC50 (µM)  
  Anti-HIV-1 activity Cytotoxicity 
1 1 > 100 – 
2 2 > 100 – 
3 3 15.3 > 100 
4 4 13.0 > 100 
5 5 14.4 > 100 
6 6 15.1 > 100 
7 7 20.7 > 100 
 
It has been reported that the parental non-sulfated lamellarins 
exhibit potent cytotoxicity on a variety of cancer cell lines via 
multiple mechanism of action.5–7 Therefore, we performed WST-
1 assays to estimate the cytotoxicity of lamellarin sulfates 3–7. 
HeLa/CD4 cells were incubated with these compounds at 100 
µM for 24 h prior to assay. No sulfates tested exhibited 
unfavorable cytotoxicity, at least under these conditions (Table 1).  
The lack of cytotoxicity of sulfates 3–7 suggested that these 
hydrophilic compounds are not incorporated in HeLa/CD4 cells. 
Recently, Cushman et al. demonstrated by LC-MS-MS analysis 
that resveratrol sulfates, which are structurally similar to 
lamellarin sulfates, displayed negligible uptake in MCF7 cells.17 
Lamellarins are UV fluorescent (Figure S2 in supplementary 
data). Therefore, we examined cellular uptake of lamellarin 
sulfates using a confocal laser scanning microscope. HeLa/CD4 
cells were treated with lamellarins 1, 3–7 at 100 µM for 24 h. 
After washing with phosphate-buffered saline (PBS) and fixing 
in 4% paraformaldehyde, the resulting cells were observed by a 
confocal laser scanning microscope. The fluorescent signal 
corresponding to the lamellarin framework was observed in the 
cells treated with lamellarin α (1) (Figure 2, A).18 However, no 
fluorescent signals were detected in the cells treated with 
lamellarin sulfates 3–7 (Figure 2, B–F). For comparison, similar 
experiments were carried out after permeabilization of the cell 
membrane with methanol. In these cases, fluorescent signals 
were observed in all cells treated with both lamellarin α (1) and 
lamellarin sulfates 3–7 (Figure 2, G–L). These results clearly 
indicate that hydrophilic lamellarin sulfates 3–7 do not pass 
through the hydrophobic cell membrane.  
Inaccessibility of lamellarin sulfates into HeLa/CD4 cells 
suggested that these compounds inhibit HIV-1 infection at the 
virus entry step rather than at the later integration step. HIV-1 
gains entry into susceptible cells by fusion of the viral membrane 
with the cell plasma membrane.19 The membrane fusion process 
between HIV-1 and target cells is initiated by the attachment of 
HIV-1 envelope glycoprotein (Env) to the receptors on the target 
cell membrane.20 The HIV-1 Env-expressing cells can fuse with 
susceptible cells by the membrane fusion activity of the Env 
protein.21,22 It is thought that the cell–cell fusion by the Env 
protein reflects the membrane fusion between virions and target 
cells.23,24 Thus, we examined the inhibitory effect of lamellarin 
sulfates on the HIV-1 Env-mediated cell–cell fusion using a co-
culture system of MAGIC 5 target cells and HIV-1 Env-
expressing 293T effector cells. The degree of inhibition was 
estimated by measuring the β-galactosidase activities of the cell 
lysates. The effects of lamellarin sulfates are summarized as a bar 
graph in Figure 3. Bar 1 indicates a negative control in which 
Env-non-expressing effector cells (no ability of cell–cell fusion) 
were employed. Bar 2 shows a positive control in which Env-
expressing effector cells were employed in the absence of 
inhibitors. On treatment with lamellarin sulfates 3–7 at 100 µM 
(bars 3–7), the β-galactosidase activities of the co-culture 
systems were reduced to the same as that of the negative control. 
In contrast, on treatment with ring-opened sulfate 2 at the same 
concentration (bar 8), the β-galactosidase activity was increased 
to the level of positive control. These results clearly indicate that 
lamellarin sulfates 3–7 inhibited cell–cell fusion at 100 µM, 
whereas ring-opened analogue 2 did not. The good correlation 
between the inhibitory effects on HIV-1 infection and on HIV-1 
Env-mediated cell–cell fusion suggested that the mechanism of 
action of lamellarin sulfates is entry inhibition rather than 
integrase inhibition.  
3. Conclusion 
A small library of anti-HIV-1 lamellarin α 20-sulfate 
analogues was prepared using a synthetic strategy developed in 
our laboratories. The structure–activity relationship study 
revealed that the pentacyclic lamellarin core and the sulfate 
group are essential for anti-HIV-1 activity. Confocal laser 
microscopic analyses and cell–cell fusion experiments suggested 
that the anti-HIV-1 activity of lamellarin sulfates are caused by 
inhibition of the virus entry step rather than the previously 
indicated integration step.  
4. Experimental section 
4.1. Synthesis–general 
Compound






















Figure 2. Confocal laser scanning microscopic observation of the cellular uptake of lamellarin α (1) and lamellarin sulfates 3–7.  Photographs A–F indicate the 
























① ② ③ ④ ⑤ ⑥ ⑦ ⑧
② DMSO treated
③ Lamellarin α 20-sulfate (4)
④ Lamellarin α 13-sulfate (5)
⑤ Lamellarin α 13,20-disulfate (6)
⑥ Lamellarin U 20-sulfate (3)
⑦ Lamellarin N 8,13,20-trisulfate (7)
⑧ Ring-opened analogue 2
① DMSO treated Effector cells without Env
Effector cells with Env
100 µM treated  
Figure 3. Effect of lamellarin sulfates on HIV-1 Env-mediated cell–cell fusion.  
 
 
Melting points are uncorrected. IR spectra are reported in 
terms of frequency of absorption (cm–1). 1H NMR spectra were 
recorded at 400 MHz and are reported relative to Me4Si (δ 0.0). 
Data for 1H NMR spectra are reported as follows: chemical shift 
(δ ppm), multiplicity, coupling constant (Hz) and integration. 13C 
NMR spectra were recorded at 100 MHz and are reported relative 
to Me4Si (δ 0.0). Data for 13C NMR spectra are reported in terms 
of chemical shift. High resolution mass spectra were measured by 
the EI or FAB method. Elemental analysis was performed for C, 
H, and N. Column chromatography was conducted on silica gel 
60N, 63-210 µm unless otherwise mentioned. Solvents were 
dried and distilled by standard methods if necessary.  





Under an argon atmosphere, a mixture of 8 (12.9 g, 20.0 
mmol), 9 (7.64 g, 24.0 mmol), Pd(PPh3)4 (462 mg, 0.400 mmol), 
Na2CO3 (14.0 g, 132 mmol), and degassed water (40 mL) in THF 
(400 mL) was refluxed for 3 h. The mixture was cooled to room 
temperature and evaporated. The products were extracted with 
dichloromethane and the extract was washed successively with 
water and brine, dried over Na2SO4, and evaporated. The residue 
was purified by column chromatography (toluene–ethyl acetate = 
10:1) to give 10 as pale brown solid (11.8 g, 77%). Mp 113.5–
115 °C; IR (KBr) 1728, 1518, 1418, 1239, 1216 cm–1; 1H NMR 
(400 MHz, CDCl3) δ 3.03 (t, J = 6.9 Hz, 2H), 3.30 (s, 3H), 3.53 
(s, 3H), 3.83 (s, 3H), 3.84 (s, 3H), 3.87 (s, 3H), 3.90 (s, 3H), 4.86 
(br s, 2H), 4.91–5.01 (m, 2H), 5.18 (s, 2H), 6.70 (d, J = 1.9 Hz, 
1H), 6.72 (dd, J = 1.9 and 8.1 Hz, 1H), 6.72 (s, 1H), 6.77 (d, J = 
8.1 Hz, 1H), 7.27–7.32 (m, 1H), 7.33–7.38 (m, 2H), 7.43–7.47 
(m, 2H); 13C NMR (100 MHz, CDCl3) δ 37.6, 48.6, 51.7, 51.8, 
55.7, 55.8, 56.0, 56.7, 71.2, 96.0, 103.9, 111.4, 112.2, 112.4, 
115.1, 117.1, 118.1 (q, J = 320 Hz), 118.4, 121.2, 124.2, 127.7, 
127.9, 128.5, 130.3, 136.2, 136.7, 144.6, 147.9, 148.7, 148.9, 
149.4, 159.3, 161.1; HRFABMS m/z calcd for C35H36F3NO13S 




2-carboxylate (11)  
To a solution of 10 (11.8 g, 15.3 mmol) in methanol (1.0 L) 
was added concd HCl (100 mL) at room temperature. After being 
refluxed for 3 h, the mixture was cooled to room temperature and 
evaporated. The residue was poured into water (200 mL) and the 
precipitates thus formed was collected by filtration, washed with 
water, and dried under reduced pressure. On the other hand, the 
filtrate was extracted with dichloromethane and the extract was 
washed with water and brine, dried over Na2SO4, and evaporated 
to give an additional demethoxymethylated product. The 
demethoxymethylated product was dissolved in dichloromethane 
(800 mL) and p-toluenesulfonic acid monohydrate (729 mg, 3.83 
mmol) was added. The mixture was refluxed for 3.5 h, cooled to 
room temperature, washed with saturated aqueous NaHCO3 and 
brine, dried over Na2SO4, and evaporated. The residue was 
purified by column chromatography (dichloromethane) to give 
11 as colorless solid (10.2 g, 96%). Recrystallization from 
dichloromethane–hexane gave colorless needles. Mp 163–
164 °C; IR (KBr) 1738, 1519, 1412, 1265, 1225 cm–1; 1H NMR 
(400 MHz, CDCl3) δ 3.04 (t, J = 7.4 Hz, 2H), 3.83 (s, 3H), 3.84 
(s, 3H), 3.88 (s, 3H), 3.95 (s, 3H), 5.14 (t, J = 7.4 Hz, 2H), 5.21 
(s, 2H), 6.65 (dd, J = 2.0 and 8.2 Hz, 1H), 6.74 (d, J = 8.2 Hz, 
1H), 6.75 (d, J = 2.0 Hz, 1H), 6.92 (s, 1H), 7.30–7.36 (m, 1H), 
7.36–7.42 (m, 2H), 7.38 (s, 1H), 7.43–7.48 (m, 2H); 13C NMR 
(100 MHz, CDCl3) δ 37.6, 48.7, 52.4, 55.8, 55.9, 56.3, 71.1, 
102.7, 105.1, 106.6, 111.3, 112.4, 115.6, 118.5 (q, J = 320 Hz), 
120.0, 121.2, 123.2, 127.3, 128.3, 128.8, 129.4, 129.6, 135.9, 
145.9, 147.2, 148.0, 149.0, 149.6, 153.8, 158.9. Anal. Calcd for 
C32H28F3NO11S: C, 55.57; H, 4.08; N, 2.03. Found: C, 55.55; H, 




b]pyrrole-2-carboxylate (13)  
According to the procedure described for the preparation of 
compound 10, 11 (5.45 g, 7.89 mmol), 12 (3.02 g, 10.3 mmol), 
and Pd(PPh3)4 (182 mg, 0.158 mmol) were reacted for 3 h. After 
chromatographic purification (hexane–ethyl acetate = 1:1–1:2), 
13 was obtained as colorless solid (5.24 g, 94%). 
Recrystallization from dichloromethane–hexane gave colorless 
powder. Mp 147–148 °C; IR (KBr) 1713, 1516, 1230, 1159 cm–1; 
1H NMR (400 MHz, CDCl3) δ 3.08 (t, J = 7.5 Hz, 2H), 3.46 (s, 
3H), 3.49 (s, 3H), 3.58 (s, 3H), 3.85 (s, 3H), 3.86 (s, 3H), 3.94 (s, 
3H), 5.10 (dd, J = 6.3 and 8.9 Hz, 2H), 5.16 (s, 2H), 5.22 (s, 2H), 
6.55 (s, 1H), 6.75–6.82 (m, 3H), 6.88 (s, 1H), 6.96 (dd, J = 1.9 
and 8.3 Hz, 1H), 7.00 (d, J = 8.3 Hz, 1H), 7.13 (d, J = 1.9 Hz, 
1H), 7.27–7.32 (m, 1H), 7.33–7.38 (m, 2H), 7.39–7.43 (m, 2H); 
13C NMR (100 MHz, CDCl3) δ 37.9, 48.7, 51.7, 55.6, 55.8, 56.0, 
56.1, 56.2, 71.0, 95.7, 102.7, 105.1, 110.0, 111.3, 111.5, 112.4, 
117.6, 119.0, 121.2, 124.1, 124.5, 126.9, 126.9, 127.3, 128.1, 
128.7, 129.5, 130.6, 136.2, 145.8, 146.3, 146.3, 147.8, 148.2, 
149.0, 149.6, 155.1, 161.3. Anal. Calcd for C40H39NO11: C, 





Under an argon atmosphere, a suspension of 13 (3.55 g, 5.00 
mmol) in a degassed mixture of 40% aqueous KOH (200 mL) 
and ethanol (200 mL) was refluxed for 2 h. The solution was 
cooled to room temperature and concentrated. The pH of the 
solution was adjusted with acetic acid (225 mL) and the product 
was extracted with dichloromethane. The extract was washed 
with water and brine, dried over Na2SO4, and evaporated. The 
residue was dissolved in dichloromethane (500 mL) and PPTS 
(1.26 g, 5.00 mmol) was added. The mixture was refluxed for 8 h, 
cooled to room temperature, and evaporated. The residue was 
purified by column chromatography (dichloromethane–methanol 
= 10:1) to give 14 as pale brown solid (2.53 g, 73%). 
Recrystallization from dichloromethane–diethyl ether hexane 
gave pale brown powder. Mp 160–200 °C (dec) (sealed 
capillary); IR (KBr) 1730, 1685, 1437, 1234, 1157 cm–1; 1H 
NMR (400 MHz, CDCl3) δ 3.07 (t, J = 7.7 Hz, 2H), 3.45 (s, 3H), 
3.45 (s, 3H), 3.79 (s, 3H), 3.81 (s, 3H), 3.91 (s, 3H), 5.11 (dd, J = 
6.3 and 9.2 Hz, 2H), 5.15 (s, 2H), 5.18 (d, J = 6.5 Hz, 1H), 5.21 
(d, J = 6.5 Hz, 1H), 6.49 (s, 1H), 6.70–6.77 (m, 2H), 6.84 (s, 1H), 
6.87 (s, 1H), 6.98 (d, J = 8.3 Hz, 1H), 7.02 (dd, J = 1.7 and 8.3 
Hz, 1H), 7.19 (d, J = 1.7 Hz, 1H), 7.27–7.32 (m, 1H), 7.32–7.38 
(m, 2H), 7.38–7.44 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 37.8, 
48.8, 55.5, 55.8, 55.9, 56.1, 56.2, 71.0, 95.7, 102.6, 105.0, 109.9, 
111.3, 111.7, 112.4, 118.1, 119.2, 121.1, 124.5, 124.6, 125.0, 
126.8, 127.0, 127.3, 128.1, 128.7, 130.6, 136.2, 145.7, 146.2, 
146.4, 147.8, 148.2, 149.0, 149.8, 155.1, 163.9. Anal. Calcd for 
C39H37NO11: C, 67.33; H, 5.36; N, 2.01. Found: C, 67.07; H, 
5.40; N, 1.95.  
4.2.5. 7-Benzyloxy-3-[2-(3,4-dimethoxyphenyl)ethyl]-8-
methoxy-1-[4-methoxy-3-(methoxymethoxy)phenyl]-
[1]benzopyrano[3,4-b]pyrrol-4(3H)-one (15)  
Under an argon atmosphere, a mixture of 14 (1.74 g, 2.50 
mmol) and copper(I) oxide (358 mg, 2.50 mmol) in quinoline (25 
mL) was heated at 220 °C for 10 min. The mixture was cooled to 
room temperature and evaporated. The residue was diluted with 
dichloromethane and the mixture was passed through a pad of 
Celite. The filtrate was washed with 1 M HCl, saturated aqueous 
NaHCO3, water, and brine, dried over Na2SO4, and evaporated. 
The residue was purified by column chromatography (hexane–
ethyl acetate = 1:1) to give 15 as pale yellow solid (1.61 g, 99%). 
Recrystallization from dichloromethane–hexane gave pale yellow 
powder. Mp 136.5–138 °C; IR (KBr) 1705, 1517, 1260, 1153 
cm–1; 1H NMR (400 MHz, CDCl3) δ 3.09 (t, J = 7.0 Hz, 2H), 
3.51 (s, 3H), 3.60 (s, 3H), 3.78 (s, 3H), 3.84 (s, 3H), 3.93 (s, 3H), 
4.62 (t, J = 7.0 Hz, 2H), 5.18 (s, 2H), 5.23 (s, 2H), 6.62 (d, J = 
1.9 Hz, 1H), 6.68 (dd, J = 1.9 and 8.1 Hz, 1H), 6.76 (s, 1H), 6.78 
(d, J = 8.1 Hz, 1H), 6.93 (s, 1H), 6.96 (d, J = 8.3 Hz, 1H), 7.02 
(dd, J = 2.0 and 8.3 Hz, 1H), 7.11 (s, 1H), 7.18 (d, J = 2.0 Hz, 
1H), 7.27–7.33 (m, 1H), 7.33–7.39 (m, 2H), 7.41–7.46 (m, 2H); 
13C NMR (100 MHz, CDCl3) δ 37.8, 50.9, 55.8, 55.9, 56.1, 56.1, 
56.4, 71.0, 95.7, 102.9, 105.4, 111.0, 111.4, 111.7, 112.1, 115.0, 
118.4, 119.0, 120.9, 123.9, 126.9, 127.1, 127.3, 128.1, 128.7, 
130.6, 131.9, 136.4, 146.0, 146.2, 146.4, 147.9, 148.0, 149.0, 
149.5, 155.5. Anal. Calcd for C38H37NO9: C, 70.03; H, 5.72; N, 
2.15. Found: C, 69.75; H, 5.81; N, 2.11.  
4.2.6. 3-Benzyloxy-8,9-dihydro-2,11,12-trimethoxy-14-[4-
methoxy-3-(methoxymethoxy)phenyl]-6H-
[1]benzopyrano[4’,3’:4,5]pyrrolo[2,1-a]isoquinolin-6-one (16)  
Under an argon atmosphere, a solution of PIFA (815 mg, 1.90 
mmol) and BF3·OEt2 (480 µL, 3.89 mmol) in dichloromethane 
(40 mL) was added dropwise to a solution of 15 (1.03 g, 1.59 
mmol) in dichloromethane (160 mL) at –40 °C. After being 
stirred for 1.5 h, the mixture was quenched with 2 M aqueous 
NH3 and allowed to warm to room temperature. The product was 
extracted with dichloromethane and the extract was washed with 
water and brine, dried over Na2SO4, and evaporated. The residue 
was purified by column chromatography (dichloromethane–ethyl 
acetate = 20:1) to give 16 as colorless solid (552 mg, 54%). 
Recrystallization from dichloromethane–diethyl ether gave 
colorless powder. Mp 223.5–225 °C; IR (KBr) 1706, 1415, 1273, 
1171 cm–1; 1H NMR (400 MHz, CDCl3) δ 3.09 (t, J = 6.8 Hz, 
2H), 3.39 (s, 3H), 3.46 (s, 3H), 3.49 (s, 3H), 3.87 (s, 3H), 3.95 (s, 
3H), 4.67–4.85 (m, 2H), 5.11 (s, 2H), 5.21 (d, J = 6.7 Hz, 1H), 
5.25 (d, J = 6.7 Hz, 1H), 6.68 (s, 1H), 6.69 (s, 1H), 6.73 (s, 1H), 
6.88 (s, 1H), 7.10 (d, J = 8.2 Hz, 1H), 7.16 (dd, J = 1.9 and 8.2 
Hz, 1H), 7.26–7.31 (m, 1H), 7.32–7.37 (m, 2H), 7.33 (d, J = 1.9 
Hz, 1H), 7.37–7.42 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 28.7, 
42.4, 55.1, 55.6, 55.9, 56.3, 56.3, 70.9, 95.7, 102.7, 105.0, 108.7, 
110.8, 111.0, 112.6, 113.7, 114.6, 119.7, 120.1, 125.4, 126.6, 
127.2, 128.0, 128.1, 128.2, 128.6, 135.9, 136.4, 145.8, 146.0, 
147.2, 147.5, 147.7, 149.0, 149.9, 155.5. Anal. Calcd for 
C38H35NO9: C, 70.25; H, 5.43; N, 2.16. Found: C, 69.97; H, 5.39; 
N, 2.03.  
4.2.7. 3-Benzyloxy-2,11,12-trimethoxy-14-[4-methoxy-3-
(methoxymethoxy)phenyl]-6H-
[1]benzopyrano[4’,3’:4,5]pyrrolo[2,1-a]isoquinolin-6-one (17)  
A solution of DDQ (66.3 mg, 0.292 mmol) in 
dichloromethane (10 mL) was added dropwise to a solution of 16 
(182 mg, 0.280 mmol) in dichloromethane (20 mL) at room 
temperature. After being refluxed for 30 h, the mixture was 
cooled to room temperature and evaporated. The residue was 
purified by column chromatography (dichloromethane–ethyl 
acetate = 20:1) to give 17 as colorless solid (158 mg, 87%). 
Recrystallization from dichloromethane–diethyl ether gave 
colorless powder. Mp 240.5–242 °C; IR (KBr) 1703, 1422, 1268, 
1173 cm–1; 1H NMR (400 MHz, CDCl3) δ 3.48 (s, 3H), 3.49 (s, 
3H), 3.51 (s, 3H), 3.94 (s, 3H), 3.99 (s, 3H), 5.08 (s, 2H), 5.26 (d, 
J = 6.7 Hz, 1H), 5.29 (d, J = 6.7 Hz, 1H), 6.73 (s, 1H), 6.87 (s, 
1H), 6.99 (d, J = 7.4 Hz, 1H), 7.02 (s, 1H), 7.14 (s, 1H), 7.18 (d, 
J = 8.2 Hz, 1H), 7.28 (dd, J = 2.0 and 8.2 Hz, 1H), 7.27–7.32 (m, 
1H), 7.33–7.38 (m, 2H), 7.38–7.42 (m, 2H), 7.45 (d, J = 2.0 Hz, 
1H), 9.14 (d, J = 7.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 
55.2, 55.5, 55.9, 56.3, 56.4, 70.8, 95.7, 102.6, 105.3, 105.5, 107.4, 
107.8, 110.3, 110.7, 112.3, 112.7, 119.1, 120.2, 123.2, 124.8, 
126.0, 127.2, 128.0, 128.4, 128.7, 129.3, 134.4, 136.3, 146.0, 
146.4, 147.3, 148.5, 149.2, 150.1, 150.2, 155.4. Anal. Calcd for 
C38H33NO9: C, 70.47; H, 5.14; N, 2.16. Found: C, 70.32; H, 5.11; 
N, 2.05.  
4.2.8. 3-Hydroxy-14-(3-hydroxy-4-methoxyphenyl)-2,11,12-
trimethoxy-6H-[1]benzopyrano[4’,3’:4,5]pyrrolo[2,1-
a]isoquinolin-6-one (lamellarin  α) (1)  
Under an argon atmosphere, a heptane solution of BCl3 (1.0 M, 
278 µL, 0.278 mmol) was added dropwise to a solution of 17 
(30.0 mg, 0.0463 mmol) in dichloromethane (3.0 mL) at –78 °C. 
After being stirred for 30 min at this temperature, the reaction 
mixture was allowed to warm to 0 °C and stirred for an additional 
3 h. The mixture was quenched with saturated aqueous NaHCO3 
and the precipitate thus formed was collected by filtration, 
washed with water, and dried under reduced pressure. The 
residue was purified by column chromatography over Sephadex 
LH-20 (acetone–methanol = 1:1) to give 1 as pale gray powder 
(23.3 mg, 98%). Mp > 300 °C (sealed capillary) (lit.10 Mp > 
260 °C); IR (KBr) 3363, 1689, 1430, 1270, 1223, 1163 cm–1; 1H 
NMR (400 MHz, DMSO-d6) δ 3.33 (s, 3H), 3.36 (s, 3H), 3.81 (s, 
3H), 3.83 (s, 3H), 6.68 (s, 1H), 6.82 (s, 1H), 6.89 (dd, J = 2.0 and 
8.2 Hz, 1H), 6.96 (d, J = 2.0 Hz, 1H), 7.07 (s, 1H), 7.12 (d, J = 
8.2 Hz, 1H), 7.14 (d, J = 7.4 Hz, 1H), 7.24 (s, 1H), 8.90 (d, J = 
7.4 Hz, 1H), 9.44 (br s, 1H), 9.90 (br s, 1H); 13C NMR (100 MHz, 
DMSO-d6) δ 54.6, 55.2, 55.7, 56.3, 103.9, 104.9, 105.8, 106.7, 
108.2, 108.4, 110.8, 112.7, 113.6, 118.3, 118.4, 122.2, 122.4, 
124.5, 127.4, 128.8, 133.7, 144.8, 146.5, 147.8, 148.0, 148.1, 
149.0, 150.1, 154.5. These spectroscopic data are identical with 
those previously reported.10  
4.2.9. 3-[2-(3,4-Dimethoxyphenyl)ethyl]-7-hydroxy-8-
methoxy-1-[4-methoxy-3-(methoxymethoxy)phenyl]-
[1]benzopyrano[3,4-b]pyrrol-4(3H)-one (18)  
Under a hydrogen atmosphere, a mixture of 15 (100 mg, 0.153 
mmol), palladium carbon (Pd: 10%, 20 mg), ethyl acetate (20 
mL) was vigorously stirred for 19 h at room temperature. The 
mixture was passed through a pad of Celite and the filtrate was 
evaporated. The residue was purified by column chromatography 
(hexane–ethyl acetate = 1:2) to give 18 as pale brown solid (85.6 
mg, 99%). Mp 70–95 °C (dec) (sealed capillary); IR (KBr) 3391, 
1708, 1516, 1259, 1154 cm–1; 1H NMR (400 MHz, CDCl3) δ 3.10 
(t, J = 7.1 Hz, 2H), 3.51 (s, 3H), 3.61 (s, 3H), 3.79 (s, 3H), 3.85 
(s, 3H), 3.93 (s, 3H), 4.63 (t, J = 7.1 Hz, 2H), 5.23 (s, 2H), 5.87 
(s, 1H), 6.64 (d, J = 1.9 Hz, 1H), 6.69 (dd, J = 1.9 and 8.1 Hz, 
1H), 6.77 (s, 1H), 6.79 (d, J = 8.1 Hz, 1H), 6.97 (d, J = 8.3 Hz, 
1H), 6.97 (s, 1H), 7.02 (dd, J = 2.0 and 8.3 Hz, 1H), 7.07 (s, 1H), 
7.18 (d, J = 2.0 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 37.8, 
51.0, 55.8, 55.9, 56.0, 56.1, 56.4, 95.7, 103.5, 104.3, 110.4, 111.4, 
111.8, 112.2, 114.9, 118.6, 118.8, 121.0, 124.0, 127.0, 127.3, 
130.6, 131.8, 143.4, 145.8, 146.4, 146.6, 147.9, 149.0, 149.5, 
155.5; HRFABMS m/z calcd for C31H31NO9 (M+) 561.1999, 
found 561.1996.  
4.2.10. 3-[2-(3,4-Dimethoxyphenyl)ethyl]-8-methoxy-1-[4-
methoxy-3-(methoxymethoxy)phenyl]-4-oxo-3,4-dihydro-
[1]benzopyrano[3,4-b]pyrrol-7-yl 2,2,2-trichloroethyl sulfate 
(19)  
Under an argon atmosphere, a solution of 2,2,2-trichloroethyl 
chlorosulfate (38.9 mg, 0.157 mmol) in dichloromethane (3 mL) 
was added dropwise to a mixture of 18 (67.8 mg, 0.121 mmol), 
DMAP (14.7 mg, 0.121 mmol), and triethylamine (25.2 µL, 
0.181 mmol) in dichloromethane (6 mL) at 0 °C. After being 
stirred for 1 h at this temperature, the reaction mixture was 
allowed to warm to room temperature and stirred for an 
additional 9 h. The mixture was quenched with water and the 
product was extracted with dichloromethane. The extract was 
washed with water and brine, dried over Na2SO4, and evaporated. 
The residue was purified by column chromatography (hexane–
ethyl acetate = 1:1) to give 19 as colorless solid (84.0 mg, 90%). 
Recrystallization from dichloromethane–diethyl ether gave 
colorless needles. Mp 121.5–122.5 °C; IR (KBr) 1713, 1406, 
1261 cm–1; 1H NMR (400 MHz, CDCl3) δ 3.11 (t, J = 7.1 Hz, 
2H), 3.51 (s, 3H), 3.60 (s, 3H), 3.81 (s, 3H), 3.86 (s, 3H), 3.94 (s, 
3H), 4.66 (t, J = 7.1 Hz, 2H), 4.94 (s, 2H), 5.23 (s, 2H), 6.65 (d, J 
= 1.8 Hz, 1H), 6.68 (dd, J = 1.8 and 8.1 Hz, 1H), 6.79 (d, J = 8.1 
Hz, 1H), 6.82 (s, 1H), 6.98 (d, J = 8.3 Hz, 1H), 7.01 (dd, J = 1.7 
and 8.3 Hz, 1H), 7.16 (d, J = 1.7 Hz, 1H), 7.23 (s, 1H), 7.46 (s, 
1H); 13C NMR (100 MHz, CDCl3) δ 37.8, 51.1, 55.8, 55.9, 56.0, 
56.1, 56.4, 80.4, 92.4, 95.7, 106.4, 111.3, 111.8, 112.0, 112.4, 
115.8, 118.3, 118.4, 119.9, 120.9, 123.9, 125.5, 126.2, 130.2, 
132.0, 137.2, 144.7, 146.5, 147.4, 147.9, 149.0, 149.7, 154.6; 




[1]benzopyrano[3,4-b]pyrrol-7-yl 2,2,2-trichloroethyl sulfate 
(20)  
To a mixture of 19 (107 mg, 0.139 mmol), dichloromethane 
(12 mL), and methanol (6.0 mL) was added concd HCl (1.0 mL). 
The mixture was stirred for 12 h at 30 °C, and evaporated. The 
precipitate thus formed was collected by filtration, washed with 
water, and dried under reduced pressure to give 20 as pale brown 
solid (95.1 mg, 94%). Recrystallization from methanol–water 
gave pale brown granules. Mp 75–105 °C (dec) (sealed 
capillary); IR (KBr) 3423, 1719, 1413, 1263 cm–1; 1H NMR (400 
MHz, DMSO-d6) δ 3.03 (t, J = 6.9 Hz, 2H), 3.58 (s, 3H), 3.67 (s, 
3H), 3.71 (s, 3H), 3.82 (s, 3H), 4.63 (t, J = 6.9 Hz, 2H), 5.35 (s, 
2H), 6.65 (dd, J = 1.7 and 8.2 Hz, 1H), 6.74 (d, J = 1.7 Hz, 1H), 
6.82 (dd, J = 2.1 and 8.2 Hz, 1H), 6.83 (d, J = 8.2 Hz, 1H), 6.90 
(d, J = 2.1 Hz, 1H), 7.05 (d, J = 8.2 Hz, 1H), 7.36 (s, 1H), 7.41 (s, 
1H), 7.67 (s, 1H), 9.35 (s, 1H); 13C NMR (100 MHz, DMSO-d6) 
δ 36.7, 49.7, 55.2, 55.4, 55.7, 55.7, 80.0, 92.8, 106.0, 111.7, 
111.9, 112.4, 112.4, 115.1, 116.6, 118.1, 119.7, 120.4, 120.7, 
124.0, 125.6, 130.1, 132.8, 136.2, 143.7, 146.5, 147.0, 147.3, 
147.4, 148.4, 153.6; HRFABMS m/z calcd for C31H29Cl3NO11S 
[(M+H)+] 728.0527, found 728.0543.  
4.2.12. Sodium 3-[2-(3,4-dimethoxyphenyl)ethyl]-1-(3-
hydroxy-4-methoxyphenyl)-8-methoxy-4-oxo-3,4-dihydro-
[1]benzopyrano[3,4-b]pyrrol-7-yl sulfate (2)  
Under an argon atmosphere, a mixture of 20 (50.0 mg, 0.0686 
mmol), ammonium formate (25.9 mg, 0.411 mmol), zinc 
(powder, 13.5 mg, 0.206 mmol), methanol (20 mL), and THF (20 
mL) was stirred for 15 h at room temperature and passed through 
a pad of Celite. The filtrate was evaporated and the residue was 
purified successively by column chromatography over Silica Gel 
60N (ethyl acetate–methanol = 3:1), column chromatography 
over Amberlite IRC-50 (Na+ form) (ethyl acetate–methanol–
water = 1:1:1), and column chromatography over Sephadex LH-
20 (ethyl acetate–methanol = 1:1) to give 2 as pale yellow 
powder (38.1 mg, 90%). Mp 170–230 °C (dec) (sealed capillary); 
IR (KBr) 3424, 1705, 1260, 1049 cm–1; 1H NMR (400 MHz, 
DMSO-d6) δ 3.03 (t, J = 7.2 Hz, 2H), 3.50 (s, 3H), 3.67 (s, 3H), 
3.71 (s, 3H), 3.81 (s, 3H), 4.61 (t, J = 7.2 Hz, 2H), 6.68 (dd, J = 
1.9 and 8.2 Hz, 1H), 6.74 (d, J = 1.9 Hz, 1H), 6.79 (dd, J = 2.1 
and 8.2 Hz, 1H), 6.85 (d, J = 8.2 Hz, 1H), 6.91 (d, J = 2.1 Hz, 
1H), 7.02 (d, J = 8.2 Hz, 1H), 7.22 (s, 1H), 7.32 (s, 1H), 7.51 (s, 
1H), 9.39 (br s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 36.7, 
49.6, 55.2, 55.3, 55.4, 55.6, 105.1, 108.8, 111.7, 112.2, 112.3, 
112.4, 114.4, 116.7, 118.8, 120.1, 120.6, 125.3, 126.1, 130.3, 
132.5, 142.2, 144.4, 146.5, 146.6, 147.1, 147.3, 148.5, 154.2; 
HRFABMS m/z calcd for C29H26NNa2O11S [(M+Na)+] 642.1022, 
found 642.1015.  
4.2.13. 8,9-Dihydro-3-Hydroxy-2,11,12-trimethoxy-14-[4-
methoxy-3-(methoxymethoxy)phenyl]-6H-
[1]benzopyrano[4’,3’:4,5]pyrrolo[2,1-a]isoquinolin-6-one (21)  
According to the procedure described for the preparation of 18, 
compound 16 (150 mg, 0.231 mmol) was hydrogenolyzed over 
palladium carbon (Pd: 10%, 30 mg) for 19 h. After 
chromatographic purification (dichloromethane–ethyl acetate = 
1:1), 21 was obtained as colorless solid (127 mg, 98%). 
Recrystallization from dichloromethane–diethyl ether gave 
colorless granules. Mp 225–245 °C (dec) (sealed capillary); IR 
(KBr) 3107, 1664, 1415, 1273, 1151 cm–1; 1H NMR (400 MHz, 
CDCl3) δ 3.10 (t, J = 6.9 Hz, 2H), 3.38 (s, 3H), 3.46 (s, 3H), 3.50 
(s, 3H), 3.89 (s, 3H), 3.95 (s, 3H), 4.67–4.76 (m, 1H), 4.78–4.87 
(m, 1H), 5.20 (d, J = 6.7 Hz, 1H), 5.23 (d, J = 6.7 Hz, 1H), 5.81 
(s, 1H), 6.63 (s, 1H), 6.68 (s, 1H), 6.75 (s, 1H), 6.94 (s, 1H), 7.10 
(d, J = 8.2 Hz, 1H), 7.16 (dd, J = 1.9 and 8.2 Hz, 1H), 7.32 (d, J 
= 1.9 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 28.7, 42.4, 55.1, 
55.6, 56.0, 56.3, 56.3, 95.8, 103.4, 104.2, 108.8, 110.3, 111.1, 
112.7, 113.7, 114.4, 120.0, 120.1, 125.6, 126.7, 128.3, 128.3, 
136.0, 143.4, 145.6, 146.5, 147.1, 147.5, 149.0, 150.0, 155.6. 
Anal. Calcd for C31H29NO9: C, 66.54; H, 5.22; N, 2.50. Found: C, 




trichloroethyl sulfate (22)  
According to the procedure described for the preparation of 19, 
compound 21 (85.0 mg, 0.152 mmol) was reacted with 2,2,2-
trichloroethyl chlorosulfate (49.0 mg, 0.197 mmol). After 
chromatographic purification (dichloromethane–ethyl acetate = 
20:1), 22 was obtained as colorless solid (116 mg, 99%). 
Recrystallization from dichloromethane–diethyl ether gave 
colorless needles. Mp 125–155 °C (dec) (sealed capillary); IR 
(KBr) 1718, 1487, 1414, 1199 cm–1; 1H NMR (400 MHz, CDCl3) 
δ 3.13 (t, J = 6.9 Hz, 2H), 3.39 (s, 3H), 3.46 (s, 3H), 3.49 (s, 3H), 
3.90 (s, 3H), 3.96 (s, 3H), 4.70–4.79 (m, 1H), 4.80–4.89 (m, 1H), 
4.92 (s, 2H), 5.21 (d, J = 6.8 Hz, 1H), 5.23 (d, J = 6.8 Hz, 1H), 
6.68 (s, 1H), 6.77 (s, 1H), 6.81 (s, 1H), 7.11 (d, J = 8.2 Hz, 1H), 
7.16 (dd, J = 1.9 and 8.2 Hz, 1H), 7.31 (d, J = 1.9 Hz, 1H), 7.42 
(s, 1H); 13C NMR (100 MHz, CDCl3) δ 28.6, 42.6, 55.1, 55.6, 
56.0, 56.0, 56.3, 80.4, 92.5, 95.7, 106.2, 108.7, 111.1, 112.3, 
112.7, 114.6, 115.3, 118.3, 119.7, 119.7, 125.4, 126.6, 126.7, 
127.6, 136.4, 137.1, 144.7, 147.3, 147.3, 147.6, 149.3, 150.2, 
154.7. Anal. Calcd for C33H30Cl3NO12S: C, 51.41; H, 3.92; N, 
1.82. Found: C, 51.70; H, 3.77; N, 1.71.  
4.2.15. 8,9-Dihydro-14-(3-hydroxy-4-methoxyphenyl)-2,11,12-
trimethoxy-6-oxo-6H-[1]benzopyrano[4’,3’:4,5]pyrrolo[2,1-
a]isoquinolin-3-yl 2,2,2-trichloroethyl sulfate (23)  
According to the procedure described for the preparation of 20, 
compound 22 (48.3 mg, 0.0626 mmol) was treated with concd 
HCl (0.8 mL) in a mixture of dichloromethane (10 mL) and 
methanol (5 mL) for 20 h to give 23 as colorless solid (42.1 mg, 
92%). Recrystallization from acetone–hexane gave colorless 
powder. Mp 230–240 °C (dec) (sealed capillary); IR (KBr) 3360, 
1713, 1413, 1213 cm–1; 1H NMR (400 MHz, DMSO-d6) δ 3.12 (t, 
J = 6.7 Hz, 2H), 3.27 (s, 3H), 3.43 (s, 3H), 3.78 (s, 3H), 3.84 (s, 
3H), 4.56–4.65 (m, 1H), 4.66–4.75 (m, 1H), 5.35 (s, 2H), 6.71 (s, 
1H), 6.90–6.95 (m, 3H), 7.00 (s, 1H), 7.18 (d, J = 8.6 Hz, 1H), 
7.69 (s, 1H), 9.42 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 
27.4, 54.4, 55.4, 55.5, 55.9, 80.0, 92.8, 105.8, 108.5, 111.6, 111.9, 
113.4, 113.7, 115.4, 117.5, 117.8, 118.8, 121.4, 125.3, 126.3, 
126.9, 135.6, 136.2, 143.8, 146.9, 147.0, 147.6, 147.8, 149.0, 
153.4; HRFABMS m/z calcd for C31H27Cl3NO11S [(M+H)+] 




sulfate (lamellarin U 20-sulfate) (3)  
According to the procedure described for the preparation of 2, 
compound 23 (100 mg, 0.138 mmol) was reacted with zinc (27.0 
mg, 0.413 mmol) and ammonium formate (52.0 mg, 0.825 mmol) 
to give 3 as pale yellow powder (60.0 mg, 71%). Mp 245–275 °C 
(dec) (sealed capillary) (lit.2g Mp 222–226 °C); IR (KBr) 3446, 
1699, 1413, 1275, 1048 cm–1; 1H NMR (400 MHz, DMSO-d6) δ 
3.08 (t, J = 6.7 Hz, 2H), 3.18 (s, 3H), 3.37 (s, 3H), 3.78 (s, 3H), 
3.80 (s, 3H), 4.54–4.72 (m, 2H), 6.69 (s, 1H), 6.72 (dd, J = 2.0 
and 8.2 Hz, 1H), 6.77 (s, 1H), 6.91 (d, J = 2.0 Hz, 1H), 6.92 (s, 
1H), 7.07 (d, J = 8.2 Hz, 1H), 7.48 (s, 1H); 13C NMR (100 MHz, 
DMSO-d6) δ 27.5, 41.9, 54.2, 55.0, 55.4, 55.8, 105.2, 108.4, 
108.8, 111.4, 112.3, 112.9, 113.0, 115.2, 117.6, 119.0, 119.7, 
126.6, 126.7, 127.0, 135.4, 141.9, 144.4, 146.7, 148.1, 148.7, 
149.5, 154.2; HRFABMS m/z calcd for C29H24NNa2O11S 
[(M+Na)+] 640.0865, found 640.0851. These spectroscopic data 
are identical with those previously reported.2g  
4.2.17. 3-Hydroxy-2,11,12-trimethoxy-14-[4-methoxy-3-
(methoxymethoxy)phenyl]-6H-
[1]benzopyrano[4’,3’:4,5]pyrrolo[2,1-a]isoquinolin-6-one (24)  
According to the procedure described for the preparation of 18, 
compound 17 (100 mg, 0.154 mmol) was hydrogenolyzed over 
palladium carbon (Pd: 10%, 20 mg) for 7 h. After 
chromatographic purification (dichloromethane–ethyl acetate = 
20:1–1:1), 24 was obtained as colorless solid (78.2 mg, 91%). 
Recrystallization from acetone–hexane gave colorless powder. 
Mp 230–250 °C (dec) (sealed capillary); IR (KBr) 3308, 1672, 
1423, 1268, 1051 cm–1; 1H NMR (400 MHz, DMSO-d6) δ 3.36 (s, 
3H), 3.38 (s, 3H), 3.39 (s, 3H), 3.85 (s, 3H), 3.90 (s, 3H), 5.22 (s, 
2H), 6.63 (s, 1H), 6.86 (s, 1H), 7.02 (s, 1H), 7.20 (dd, J = 2.0 and 
8.3 Hz, 1H), 7.22 (d, J = 7.4 Hz, 1H), 7.29 (d, J = 8.3 Hz, 1H), 
7.33 (s, 1H), 7.35 (d, J = 2.0 Hz, 1H), 8.99 (d, J = 7.4 Hz, 1H), 
9.84 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 54.3, 54.8, 55.5, 
55.6, 56.0, 94.9, 103.6, 104.5, 105.4, 106.5, 108.0, 108.1, 110.2, 
112.5, 113.6, 118.1, 119.8, 122.0, 124.3, 125.5, 127.1, 128.8, 
133.5, 144.5, 146.2, 146.6, 147.8, 148.9, 149.8, 150.2, 154.2; 





sulfate (25)  
According to the procedure described for the preparation of 19, 
compound 24 (75.0 mg, 0.135 mmol) was reacted with 2,2,2-
trichloroethyl chlorosulfate (43.3 mg, 0.175 mmol). After 
chromatographic purification (dichloromethane–ethyl acetate = 
20:1), 25 was obtained as colorless solid (103 mg, 99%).  
Recrystallization from dichloromethane–diethyl ether gave 
colorless needles. Mp 175–195 °C (dec) (sealed capillary); IR 
(KBr) 1712, 1486, 1415, 1271, 1042 cm–1; 1H NMR (400 MHz, 
CDCl3) δ 3.48 (s, 3H), 3.50 (s, 3H), 3.51 (s, 3H), 3.99 (s, 3H), 
4.00 (s, 3H), 4.92 (s, 2H), 5.26 (d, J = 6.8 Hz, 1H), 5.28 (d, J = 
6.8 Hz, 1H), 6.89 (s, 1H), 7.06 (d, J = 7.3 Hz, 1H), 7.08 (s, 1H), 
7.14 (s, 1H), 7.20 (d, J = 8.2 Hz, 1H), 7.27 (dd, J = 2.0 and 8.2 
Hz, 1H), 7.42 (s, 1H), 7.44 (d, J = 2.0 Hz, 1H), 9.16 (d, J = 7.3 
Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 55.2, 55.6, 56.0, 56.4, 
56.4, 80.4, 92.4, 95.7, 105.2, 106.9, 107.5, 108.3, 111.6, 112.4, 
112.8, 113.3, 118.0, 119.1, 120.0, 123.0, 124.8, 125.8, 127.6, 
127.8, 134.5, 137.8, 145.2, 147.3, 147.4, 149.4, 150.4, 150.4, 
154.6; HRFABMS m/z calcd for C33H29Cl3NO12S [(M+H)+] 
768.0476, found 768.0466.  
4.2.19. 14-(3-Hydroxy-4-methoxyphenyl)-2,11,12-trimethoxy-
6-oxo-6H-[1]benzopyrano[4’,3’:4,5]pyrrolo[2,1-a]isoquinolin-
3-yl 2,2,2-trichloroethyl sulfate (26)  
According to the procedure described for the preparation of 20, 
compound 25 (94.3 mg, 0.123 mmol) was treated with concd 
HCl (0.8 mL) in a mixture of dichloromethane (10 mL) and 
methanol (5 mL) for 20 h to give 26 as colorless solid (87.5 mg, 
98%). Recrystallization from acetone–hexane gave colorless 
powder. Mp 235–245 °C (dec) (sealed capillary); IR (KBr) 3517, 
1711, 1487, 1414, 1271 cm–1; 1H NMR (400 MHz, DMSO-d6) δ 
3.37 (s, 3H), 3.47 (s, 3H), 3.84 (s, 3H), 3.87 (s, 3H), 5.37 (s, 2H), 
6.94 (s, 1H), 6.96 (dd, J = 1.6 and 8.2 Hz, 1H), 7.02 (d, J = 1.6 
Hz, 1H), 7.16 (s, 1H), 7.18 (d, J = 8.2 Hz, 1H), 7.25 (d, J = 7.4 
Hz, 1H), 7.32 (s, 1H), 7.69 (s, 1H), 8.92 (d, J = 7.4 Hz, 1H), 9.44 
(s, 1H); 13C NMR (100 MHz, DMSO-d6) δ 54.4, 55.4, 55.5, 56.0, 
80.0, 92.8, 104.6, 106.5, 107.3, 108.0, 111.8, 112.0 113.4, 113.4, 
117.4, 118.0, 118.1, 121.8, 121.8, 124.2, 126.3, 126.4, 133.4, 
137.0, 144.4, 147.0, 147.7, 148.1, 149.0, 150.0, 153.3; 
HRFABMS m/z calcd for C31H25Cl3NO11S [(M+H)+] 724.0214, 
found 724.0207.  
4.2.20. Sodium 14-(3-hydroxy-4-methoxyphenyl)-2,11,12-
trimethoxy-6-oxo-6H-[1]benzopyrano[4’,3’:4,5]pyrrolo[2,1-
a]isoquinolin-3-yl sulfate (lamellarin α  20-sulfate) (4)  
According to the procedure described for the preparation of 2, 
compound 26 (60.0 mg, 0.0828 mmol) was reacted with zinc 
(16.2 mg, 0.248 mmol) and ammonium formate (31.3 mg, 0.497 
mmol) to give 4 as pale yellow powder (50.2 mg, 99%). Physical 




a]isoquinolin-6-one (27)  
According to the procedure described for the preparation of 20, 
compound 17 (100 mg, 0.154 mmol) was treated with concd HCl 
(1.0 mL) in a mixture of dichloromethane (12 mL) and methanol 
(6 mL) for 19 h to give 27 as colorless solid (90.1 mg, 97%). 
Recrystallization from acetone gave colorless powder. Mp 290–
300 °C (dec) (sealed capillary); IR (KBr) 3553, 1690, 1430, 1270, 
1219, 1168 cm–1; 1H NMR (400 MHz, DMSO-d6) δ 3.37 (s, 3H), 
3.39 (s, 3H), 3.86 (s, 3H), 3.86 (s, 3H), 5.14 (s, 2H), 6.78 (s, 1H), 
7.00 (dd, J = 2.1 and 8.0 Hz, 1H), 7.02 (d, J = 2.1 Hz, 1H), 7.16 
(s, 1H), 7.17 (s, 1H), 7.21 (d, J = 8.0 Hz, 1H), 7.27 (d, J = 7.4 Hz, 
1H), 7.32–7.37 (m, 1H), 7.37 (s, 1H), 7.38–7.42 (m, 2H), 7.42–
7.47 (m, 2H), 9.01 (d, J = 7.4 Hz, 1H), 9.40 (s, 1H); 13C NMR 
(100 MHz, DMSO-d6) δ 54.4, 54.8, 55.5, 56.0, 69.9, 102.2, 104.7, 
105.2, 106.7, 108.0, 109.3, 110.9, 112.7, 113.4, 118.1, 118.1, 
122.0, 122.0, 124.3, 127.0, 127.8, 127.9, 128.2, 128.4, 133.4, 
136.4, 145.4, 145.9, 147.6, 147.9, 148.3, 148.8, 149.9, 154.1; 




methoxyphenyl 2,2,2-trichloroethyl sulfate (28)  
According to the procedure described for the preparation of 19, 
compound 27 (80.0 mg, 0.133 mmol) was reacted with 2,2,2-
trichloroethyl chlorosulfate (42.7 mg, 0.172 mmol). After 
chromatographic purification (dichloromethane–ethyl acetate = 
20:1), 28 was obtained as pale brown solid (106 mg, 98%). 
Recrystallization from dichloromethane–diethyl ether gave 
colorless powder. Mp 237.5–239 °C (sealed capillary); IR (KBr) 
1703, 1418, 1269, 1167, 1008 cm–1; 1H NMR (400 MHz, CDCl3) 
δ 3.51 (s, 3H), 3.53 (s, 3H), 3.92 (s, 3H), 4.04 (s, 3H), 5.02 (s, 
2H), 5.02 (d, J = 10.7 Hz, 1H), 5.06 (d, J = 10.7 Hz, 1H), 6.55 (s, 
1H), 6.78 (s, 1H), 6.97 (s, 1H), 6.98 (d, J = 7.2 Hz, 1H), 7.01 (s, 
1H), 7.27–7.32 (m, 1H), 7.32 (d, J = 8.4 Hz, 1H), 7.33–7.41 (m, 
4H), 7.62 (dd, J = 2.2 and 8.4 Hz, 1H), 7.80 (d, J = 2.2 Hz, 1H), 
9.09 (d, J = 7.2 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 55.3, 
55.6, 55.9, 56.6, 70.7, 80.4, 92.5, 102.5, 104.9, 105.1, 107.5, 
107.9, 108.6, 109.8, 112.5, 113.7, 118.7, 123.1, 124.8, 126.9, 
127.1, 128.1, 128.7, 129.1, 129.3, 132.7, 134.4, 136.2, 139.3, 
146.1, 146.3, 148.6, 149.4, 150.2, 151.4, 155.2; HRFABMS m/z 
calcd for C38H31Cl3NO11S [(M+H)+] 814.0683, found 814.0709.  
4.2.23. 5-{3-Hydroxy-2,11,12-trimethoxy-6-oxo-6H-
[1]benzopyrano[4’,3’:4,5]pyrrolo[2,1-a]isoquinolin-14-yl}-2-
methoxyphenyl 2,2,2-trichloroethyl sulfate (29)  
Under an argon atmosphere, a heptane solution of BCl3 (1.0 M, 
376 µL, 0.376 mmol) was added dropwise to a solution of 28 
(102 mg, 0.125 mmol) in dichloromethane (10 mL) at –78 °C. 
After being stirred for 30 min at this temperature, the reaction 
mixture was allowed to warm to 0 °C and stirred for an additional 
1 h. The mixture was quenched with saturated aqueous NaHCO3 
and the precipitate thus formed was collected by filtration, 
washed with water, and dried under reduced pressure to give 29 
as colorless solid (89.0 mg, 98%). Recrystallization from 
acetone–hexane gave colorless powder. Mp 285–295 °C (dec) 
(sealed capillary); IR (KBr) 3310, 1675, 1423, 1267, 1200 cm–1; 
1H NMR (400 MHz, DMSO-d6) δ 3.37 (s, 3H), 3.40 (s, 3H), 3.85 
(s, 3H), 4.02 (s, 3H), 5.34 (s, 2H), 6.50 (s, 1H), 6.85 (s, 1H), 6.90 
(s, 1H), 7.25 (d, J = 7.4 Hz, 1H), 7.35 (s, 1H), 7.59 (d, J = 8.5 Hz, 
1H), 7.68 (dd, J = 2.1 and 8.5 Hz, 1H), 7.87 (d, J = 2.1 Hz, 1H), 
9.00 (d, J = 7.4 Hz, 1H), 9.86 (br s, 1H); 13C NMR (100 MHz, 
DMSO-d6) δ 54.3, 54.8, 55.5, 56.7, 79.8, 92.8, 103.7, 104.2, 
104.9, 106.6, 107.8, 108.1, 108.5, 112.7, 114.9, 117.9, 122.0, 
124.3, 125.9, 127.6, 128.9, 132.6, 133.6, 138.6, 144.6, 146.1, 
147.8, 148.9, 149.9, 151.3, 154.1; HRFABMS m/z calcd for 
C31H25Cl3NO11S [(M+H)+] 724.0214, found 724.0241.  
4.2.24. Sodium 5-{3-hydroxy-2,11,12-trimethoxy-6-oxo-6H-
[1]benzopyrano[4’,3’:4,5]pyrrolo[2,1-a]isoquinolin-14-yl}-2-
methoxyphenyl sulfate (lamellarin α  13-sulfate) (5)  
According to the procedure described for the preparation of 2, 
compound 29 (60.0 mg, 0.138 mmol) was reacted with zinc (16.2 
mg, 0.248 mmol) and ammonium formate (31.3 mg, 0.497 mmol) 
to give 5 as pale yellow powder (27.8 mg, 55%). Physical and 
spectroscopic data of this compound have been reported 
previously.12  
4.2.25. Disodium salt of 2,11,12-trimethoxy-14-[4-methoxy-3-
(sulfooxy)phenyl]-3-(sulfooxy)-6H-
[1]benzopyrano[4’,3’:4,5]pyrrolo[2,1-a]isoquinolin-6-one 
(lamellarin α  13,20-disulfate) (6)  
Under an argon atmosphere, a mixture of 1 (40.0 mg, 0.0779 
mmol), sulfur trioxide pyridine complex (2.78 g, 17.4 mmol), 
DMF (2.0 mL), and pyridine (0.5 mL) was stirred for 9 h at 
65 °C. After being cooled to room temperature, the reaction 
mixture was evaporated. To the residue was added saturated 
aqueous NaHCO3 until the pH of the solution reached about 8 
and the solution was evaporated. The residue was suspended in 
methanol and the mixture was passed through a pad of Celite. 
The filtrate was evaporated and the residue was purified by 
column chromatography over Sephadex LH-20 (ethyl acetate–
methanol = 1:1) to give 6 as pale yellow powder (44.7 mg, 80%). 
Physical and spectroscopic data of this compound have been 
reported previously.12  
4.2.26. Trisodium salt of 2,12-dimethoxy-14-[4-methoxy-3-
(sulfooxy)phenyl]-3,11-bis(sulfooxy)-6H-
[1]benzopyrano[4’,3’:4,5]pyrrolo[2,1-a]isoquinolin-6-one 
(lamellarin N 8,13,20-trisulfate) (7)  
According to the procedure described for the preparation of 
compound 6, 30 (38.9 mg, 0.0779 mmol) was reacted with sulfur 
trioxide pyridine complex (4.17 g, 26.2 mmol). After 
chromatographic purification over Sephadex LH-20 (methanol), 
7 was obtained as pale yellow powder (56.4 mg, 90%). Mp 265–
295 °C (dec) (sealed capillary); IR (KBr) 1698, 1433, 1258, 1050 
cm–1; 1H NMR (400 MHz, DMSO-d6) δ 3.39 (s, 6H), 3.88 (s, 3H), 
6.75 (s, 1H), 7.16 (s, 1H), 7.24 (dd, J = 1.8 and 8.2 Hz, 1H), 7.33 
(d, J = 7.3 Hz, 1H), 7.34 (d, J = 8.2 Hz, 1H), 7.58 (s, 1H), 7.75 (d, 
J = 1.8 Hz, 1H), 7.91 (s, 1H), 9.07 (d, J = 7.3 Hz, 1H); 13C NMR 
(100 MHz, DMSO-d6) δ 54.6, 55.0, 56.2, 105.4, 105.6, 107.3, 
108.7, 111.6, 111.7, 113.1, 114.1, 117.2, 120.2, 121.9, 123.1, 
123.3, 126.1, 126.2, 128.1, 133.4, 142.9, 143.7, 143.7, 144.9, 
146.8, 150.4, 150.7, 154.3; HRFABMS m/z calcd for 
C28H18NNa4O17S3 [(M+Na)+] 827.9328, found 827.9341.  
4.3. Biological assays–general 
293T, HeLa, Cos7, and MAGIC 5 cells were cultured in 
Dulbecco’s modified Eagle’s medium (Wako) containing 8% 
fetal bovine serum (FBS) at 37 °C in 5 % CO2. HeLa cells stably 
expressing CD4 (HeLa/CD4) were constructed as follows. 293T 
cells were transfected with the MLV gag-pol, CD4-encoding 
retroviral vector, and VSV-G expression plasmids by TransIT 
LT-1 reagent (Mirus). The cells were washed 24 h after 
transfection, and cultured for 24 h in fresh medium. Culture 
supernatant of the transfected cells was inoculated into HeLa 
cells. The inoculated cells were selected by puromycin (10 
µg/ml). The puromycin-resistant cell pool was utilized in this 
study.25  
4.4. Assay of Anti-HIV-1 activity 
To obtain the LacZ-containing HIV-1 vector, Cos7 cells were 
transfected with the HXB2 Env, R8.91, and pTY-EFnLacZ 
expression plasmids using the FuGENE HD transfection reagent 
(Roche). The transfected cells were washed with medium 24 hr 
after transfection, and continued to be cultured in fresh medium 
for 24 h. HeLa/CD4 cells were plated into a 6-cm culture dish, 
and cultured for 24 h. HeLa/CD4 cells were pretreated with the 
various lamellarin sulfate analogues 5 h before HIV-1 vector 
infection. Then, HeLa/CD4 cells were inoculated with the culture 
supernatants of the transfected cells in presence of the lamellarin 
sulfate analogues. The inoculated cells were stained with 5-
bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal) 
(Wako) 2 days after inoculation. Blue cells were counted to 
estimate transduction titer.  
4.5. Cytotoxicity assay 
HeLa/CD4 cells were cultured onto a 96-well tissues culture 
plate for 2 days. Cells were treated with various lamellarin 
sulfate analogues (100 µM) for 24 h. Cells were washed twice 
with PBS and cultured with medium containing WST-1 reagent 
(Roche) for 2 hr. After the incubation, absorbance of cells was 
detected at 450 and 650 nm by a micro plate reader (BIO RAD).  
4.6. Confocal laser scanning microscopic observation  
HeLa/CD4 cells were cultured on four-well culture slides for 
24 h. Cells were permeabilizated with methanol (Wako). 
Permeabilizated or unpermeabilizated cells were cultured with 
the various lamellarin sulfate analogues (100 µM) for 24 h, 
washed with PBS and fixed in 4 % paraformaldehyde (Wako). 
Cells were observed using a confocal fluorescence microscope 
(Leica). The cells were scanned with laser light (400 nm), and 
fluorescence wavelength from 450 to 500 nm was detected.  
4.7. Assay of HIV-1 Env-mediated cell–cell fusion 
MAGIC 5 cells were plated onto a 6-cm dish and cultured for 
2 days. The MAGIC 5 cells contain the β-galactosidase gene 
under control of HIV-1 LTR.26 Cos7 cells were transfected with 
the mNDK Env expression plasmid by the transfection reagent 
FuGENE HD. MAGIC 5 cells were pretreated with the various 
lamellarin sulfate analogues (100 µM) 5 h before coculturing. 
The transfected cells were washed with medium 24 h after 
transfection to remove the transfection reagent, and then MAGIC 
5 cells were added onto the transfected Cos7 cells in presence of 
lamellarin sulfate analogues. The Env expression plasmid 
additionally encodes the tat gene. If these cells fuse, the Tat 
protein activates the HIV-1 LTR and induces  β-galactosidase 
expression. β-Galactosidase activity of cell lysates was measured 
24 h after mixed culture by the high sensitive β-galactosidase 
activity kit (Stratagene).  
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